Overview Dividends

(IRMD) Iradimed - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266A1097

Infusion Pump, Monitoring System, Detection Device, Accessories

Health Care Equipment
Market Cap in USD: 1,238m

IPO / Inception: 2014-07-16
Return 12m vs S&P 500: 47.5%

EPS (Earnings per Share)

EPS CAGR: 9.89%
EPS Trend: 83.5%

Last SUE: 0.31
Qual. Beats: 0

Revenue

Rev. CAGR: 16.72%
Rev. Trend: 98.0%

Last SUE: 4.00
Qual. Beats: 3

Dividends

Dividend Yield	1.18%
Yield on Cost 5y	5.56%
Yield CAGR 5y	5.67%
Payout Consistency	85.1%
Payout Ratio	58.4%

Risk via 5d forecast
Volatility	35.1%
Value at Risk 5%th	52.4%
Relative Tail Risk	-9.25%

Reward TTM
Sharpe Ratio	1.70
Alpha	66.35
CAGR/Max DD	2.00

Character TTM
Hurst Exponent	0.490
Beta	0.716
Beta Downside	0.585

Drawdowns 3y
Max DD	26.28%
Mean DD	7.93%
Median DD	6.84%

Description: IRMD Iradimed November 18, 2025

IradiMed Corp. (NASDAQ: IRMD) designs and sells MRI-compatible medical devices-including the MRidium IV infusion pump system, vital-signs monitors, ferromagnetic detection units, and related disposables-to hospitals, acute-care centers, and outpatient imaging facilities in the U.S. and abroad. Sales are executed via a hybrid model of direct field reps, regional directors, clinical application specialists, and independent distributors.

From a financial standpoint, the company reported FY 2023 revenue of roughly **$210 million**, representing a **~12 % year-over-year increase** driven primarily by higher adoption of its MRidium platform in large academic hospitals. Gross margins have remained stable around **55 %**, reflecting the premium pricing of MRI-compatible hardware and the recurring nature of disposable consumables.

Key sector dynamics that influence IRMD’s growth prospects include: (1) the **global MRI market’s projected CAGR of ~6 % through 2028**, fueled by rising diagnostic imaging demand and aging populations; (2) **hospital capital-expenditure cycles**, which tend to favor MRI-compatible equipment as institutions upgrade older, non-compatible devices; and (3) **reimbursement policy uncertainty**, especially around bundled payments for imaging suites, which can affect adoption speed of higher-cost compatible solutions.

Given the company’s niche positioning and the broader expansion of the MRI ecosystem, a deeper quantitative dive-such as the one offered on ValueRay-could help you evaluate the risk-adjusted upside more rigorously.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (21.2m TTM) > 0 and > 6% of Revenue (6% = 4.83m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 89.58% (prev 92.87%; Δ -3.29pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.22 (>3.0%) and CFO 25.0m > Net Income 21.2m (YES >=105%, WARN >=100%)

Net Debt (-56.5m) to EBITDA (27.8m) ratio: -2.04 <= 3.0 (WARN <= 3.5)

Current Ratio 6.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (12.9m) change vs 12m ago 0.64% (target <= -2.0% for YES)

Gross Margin 77.07% (prev 77.14%; Δ -0.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 77.06% (prev 75.66%; Δ 1.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -51.37 (EBITDA TTM 27.8m / Interest Expense TTM -514.0k) >= 6 (WARN >= 3)

Altman Z'' 11.96

(A) 0.63 = (Total Current Assets 84.9m - Total Current Liabilities 12.8m) / Total Assets 114.7m

(B) 0.58 = Retained Earnings (Balance) 66.3m / Total Assets 114.7m

(D) 4.05 = Book Value of Equity 66.3m / Total Liabilities 16.4m

Total Rating: 11.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.48

1. Piotroski 3.50pt

2. FCF Yield 1.21%

3. FCF Margin 17.76%

4. Debt/Equity 0.00

5. Debt/Ebitda -2.04

6. ROIC - WACC (= 13.19)%

7. RoE 22.93%

8. Rev. Trend 97.97%

9. EPS Trend 83.53%

What is the price of IRMD shares?

As of January 09, 2026, the stock is trading at USD 100.00 with a total of 83,386 shares traded.
Over the past week, the price has changed by +4.71%, over one month by +5.28%, over three months by +31.03% and over the past year by +74.52%.

Is IRMD a buy, sell or hold?

Iradimed has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy IRMD.

Strong Buy: 1
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the IRMD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	99	-1%
Analysts Target Price	99	-1%
ValueRay Target Price	150.3	50.3%

IRMD Fundamental Data Overview January 03, 2026

P/E Trailing = 58.9576
P/E Forward = 45.8716
P/S = 15.3707
P/B = 12.5825
P/EG = 4.46
Beta = 1.076
Revenue TTM = 80.5m USD
EBIT TTM = 26.4m USD
EBITDA TTM = 27.8m USD
Long Term Debt = 154.7k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 153.3k USD (from shortTermDebt, last fiscal year)
Debt = 154.7k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -56.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.18b USD (1.24b + Debt 154.7k - CCE 56.5m)
Interest Coverage Ratio = -51.37 (Ebit TTM 26.4m / Interest Expense TTM -514.0k)
FCF Yield = 1.21% (FCF TTM 14.3m / Enterprise Value 1.18b)
FCF Margin = 17.76% (FCF TTM 14.3m / Revenue TTM 80.5m)
Net Margin = 26.31% (Net Income TTM 21.2m / Revenue TTM 80.5m)
Gross Margin = 77.07% ((Revenue TTM 80.5m - Cost of Revenue TTM 18.5m) / Revenue TTM)
Gross Margin QoQ = 77.80% (prev 78.17%)
Tobins Q-Ratio = 10.30 (Enterprise Value 1.18b / Total Assets 114.7m)
Interest Expense / Debt = 221.4% (Interest Expense 342.4k / Debt 154.7k)
Taxrate = 23.58% (1.72m / 7.30m)
NOPAT = 20.2m (EBIT 26.4m * (1 - 23.58%))
Current Ratio = 6.64 (Total Current Assets 84.9m / Total Current Liabilities 12.8m)
Debt / Equity = 0.00 (Debt 154.7k / totalStockholderEquity, last quarter 98.4m)
Debt / EBITDA = -2.04 (Net Debt -56.5m / EBITDA 27.8m)
Debt / FCF = -3.95 (Net Debt -56.5m / FCF TTM 14.3m)
Total Stockholder Equity = 92.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.28% (Net Income 21.2m / Total Assets 114.7m)
RoE = 22.93% (Net Income TTM 21.2m / Total Stockholder Equity 92.4m)
RoCE = 28.53% (EBIT 26.4m / Capital Employed (Equity 92.4m + L.T.Debt 154.7k))
RoIC = 21.84% (NOPAT 20.2m / Invested Capital 92.4m)
WACC = 8.65% (E(1.24b)/V(1.24b) * Re(8.65%) + (debt cost/tax rate unavailable))
Discount Rate = 8.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.47%
[DCF Debug] Terminal Value 75.35% ; FCFF base≈15.4m ; Y1≈14.7m ; Y5≈14.2m
Fair Price DCF = 22.33 (EV 227.6m - Net Debt -56.5m = Equity 284.1m / Shares 12.7m; r=8.65% [WACC]; 5y FCF grow -6.01% → 3.0% )
EPS Correlation: 83.53 | EPS CAGR: 9.89% | SUE: 0.31 | # QB: 0
Revenue Correlation: 97.97 | Revenue CAGR: 16.72% | SUE: 4.0 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.46 | Chg30d=N/A | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=2.12 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+13.7% | Growth Revenue=+10.1%

Additional Sources for IRMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle